Detoxification of Mitochondrial Oxidants and Apoptotic Signaling Are Facilitated by Thioredoxin-2 and Peroxiredoxin-3 during Hyperoxic Injury

Benjamin J. Forred¹, Darwin R. Daugaard¹, Brianna K. Titus¹, Ryan R. Wood¹, Miranda J. Floen¹, Michelle L. Booze¹, Peter F. Vitiello¹,²*

¹ Children’s Health Research Center, Sanford Research, Sioux Falls, South Dakota, United States of America, ² Department of Pediatrics, University of South Dakota Sanford School of Medicine, Sioux Falls, South Dakota, United States of America

* peter.vitiello@sanfordhealth.org

Abstract

Mitochondria play a fundamental role in the regulation of cell death during accumulation of oxidants. High concentrations of atmospheric oxygen (hyperoxia), used clinically to treat tissue hypoxia in premature newborns, is known to elicit oxidative stress and mitochondrial injury to pulmonary epithelial cells. A consequence of oxidative stress in mitochondria is the accumulation of peroxides which are detoxified by the dedicated mitochondrial thioredoxin system. This system is comprised of the oxidoreductase activities of peroxiredoxin-3 (Prx3), thioredoxin-2 (Trx2), and thioredoxin reductase-2 (TrxR2). The goal of this study was to understand the role of the mitochondrial thioredoxin system and mitochondrial injuries during hyperoxic exposure. Flow analysis of the redox-sensitive, mitochondrial-specific fluorophore, MitoSOX, indicated increased levels of mitochondrial oxidant formation in human adenocarcinoma cells cultured in 95% oxygen. Increased expression of Trx2 and TrxR2 in response to hyperoxia were not attributable to changes in mitochondrial mass, suggesting that hyperoxic upregulation of mitochondrial thioredoxin prevents accumulation of oxidized Prx3. Mitochondrial oxidoreductase activities were modulated through pharmacological inhibition of TrxR2 with auranofin and genetically through shRNA knockdown of Trx2 and Prx3. Diminished Trx2 and Prx3 expression was associated with accumulation of mitochondrial superoxide; however, only shRNA knockdown of Trx2 increased susceptibility to hyperoxic cell death and increased phosphorylation of apoptosis signal-regulating kinase-1 (ASK1). In conclusion, the mitochondrial thioredoxin system regulates hyperoxic-mediated death of pulmonary epithelial cells through detoxification of oxidants and regulation of redox-dependent apoptotic signaling.

Introduction

Transitioning from an in utero environment to life outside the womb is marked by change from a relatively hypoxic environment to an oxygen-rich atmosphere. Lungs of prematurely
born infants are underdeveloped with fewer alveoli and lower expression of antioxidant enzymes [1]. Consequently, preterm infants are at a disadvantage in coping with this oxidative transition, even before therapeutic interventions such as supplemental oxygen (hyperoxia) and mechanical ventilation are considered. Bronchopulmonary dysplasia (BPD) is caused, in part, by sustained oxygen therapy in preterm infants and is marked by alveolar simplification [2, 3]. Disrupted perinatal alveolar growth may be mediated by loss of alveolar type 2 (AT2) epithelial cells through either apoptosis or altered programming associated with exposure to or recovery from excess oxygen [4–6]. Hyperoxic cellular injuries are manifested in part through generation and accumulation of reactive oxygen species (ROS) [7]. Although BPD is associated with prematurity, ROS generation and oxidative injury to the alveolar epithelium is also a component of additional lung diseases such as acute respiratory distress syndrome and acute lung injury [8].

Mitochondria are considered a major site of ROS production since ρ0 cells fail to generate ROS during hyperoxic culture [9, 10]. Electron transport chain complexes I and III are likely the predominant sources of mitochondrial ROS production during hyperoxic injury [11]. Although ROS accumulation may not be an absolute determinant, oxidants are thought to promote hyperoxic-mediated cell death through activation of pro-apoptotic Bcl-2 family proteins [12]. Cells deficient in Bax or Bak do not undergo apoptosis in response to hyperoxia [10, 13]. Furthermore, anti-apoptotic Bcl-2 proteins such as Bcl-XL and Mcl-1 can abrogate Bax-dependent hyperoxic cell death [14–16]. Collectively, these data support a functional relationship between respiring mitochondria and activation of pro-apoptotic Bcl-2 proteins which may mediate susceptibility to hyperoxic cell death.

Multiple endogenous enzyme systems work in coordination based on both target specificity and catalytic rate to maintain redox homeostasis in the mitochondrial matrix. Superoxide radical formed as a byproduct of oxidative phosphorylation (OXPHOS) is rapidly converted by superoxide dismutase 2 (SOD2) to hydrogen peroxide. Peroxiredoxin-3 (Prx3) is the primary oxidoreductase for reducing hydrogen peroxide in the matrix and reacts more efficiently than either catalase or glutathione peroxidase. In fact, it is estimated that Prx3 scavenges 90% of all peroxides in the mitochondrial matrix [17]. However, Prx3 can also reduce peroxynitrite, alkylhydroperoxides, as well as peroxides found on amino acids and proteins [18]. Similar to all 2-cysteine peroxiredoxins, the peroxidatic cysteine of Prx3 reacts with hydrogen peroxide to first form a sulfenic acid intermediate. This subsequently forms a disulfide with a resolving cysteine to form the oxidized Prx3 homodimer [19]. Regeneration of reduced monomeric Prx3 is dependent on thioredoxin-2 (Trx2), an enzyme which is recycled by thioredoxin reductase-2 (TrxR2) using electrons from NADPH. Because of its fundamental role in peroxide detoxification, the oxidoreductase activity of Trx2 prevents mitochondrial-dependent cell death mediated by various oxidant stimuli, including tert-butylhydroperoxide, etoposide, kanamycin, TNF-α, and excitotoxicity [20–25]. One proposed mechanism of cytoprotection against oxidative damage is that Trx2 binds and inhibits apoptosis signal-regulating kinase-1 (ASK1) [26, 27]. Trx2 oxidation or displacement by thioredoxin interacting protein (TXNIP) relieves ASK1 inhibition which subsequently initiates caspase-dependent apoptosis [28]. Alternatively, Trx2 may directly prevent activation of the mitochondrial permeability transition pore (MPTP) [23].

In this study we examined the role of Trx2 and Prx3 during hyperoxic injury in human lung epithelial cells. Oxidized Trx2 and Prx3 accumulated during hyperoxia which was associated with increased mitochondrial ROS (mtROS). Furthermore, genetic or pharmacologic inhibition of redox cycling via TrxR2 increased susceptibility to hyperoxic cell death and was associated with generation of mtROS and activation of the MPTP. Only Trx2 disruption, and not Prx3, correlated with activation of pro-apoptotic signaling via ASK1. Our data indicate that Prx3 serves as a primary sensor of mtROS to relieve Trx2 inhibition of ASK1, thereby promoting hyperoxic cell death.
Materials and Methods

Cell Culture and Treatment

Human lung adenocarcinoma A549 [29] and H1299 [30] cells (obtained in October 2009 from ATCC; CCL-185 and CRL-5803) were cultured in 5% CO\textsubscript{2} at 37°C in high glucose (25 mM) DMEM with 10% fetal bovine serum, 50 U/mL penicillin, 50 μg/mL streptomycin and 20 μg/mL gentamycin. During hyperoxic exposure, cells were cultured in a Plexiglas chamber flooded with 95% O\textsubscript{2}/5% CO\textsubscript{2}. For treatments, cells were pre-treated with indicated doses of MitoTEMPO and auranofin (AFN; Sigma Aldrich) prior to hyperoxic exposure. During chronic exposures, MitoTEMPO was supplemented every 24 hrs without changing culture media.

Flow Cytometry

Cells were pulsed with 5 μM MitoSOX Red or 1 nM TMRE (tetramethylrhodamine, ethyl ester) and 10 nM TO-PRO-3 (Thermo Fisher Scientific). A minimum of 10,000 live events were collected using an Accuri C6 (BD Biosciences) and analyzed using CSampler (BD Biosciences) and FCS Express4 Flow Research edition software (DeNovo). For MitoSOX Red and TMRE experiments, dyes were excited at 488 nm and emitted fluorescence was detected using the FL2 (585/40 nm) and the FL3 (670 LP) filters, respectively.

SDS-PAGE & Immunoblot

As previously described [31], cell lysates were diluted in Laemmli buffer, separated by polyacrylamide gel electrophoresis (SDS-PAGE), and transferred to PVDF membranes. Membranes were blocked in 5% non-fat dry milk before incubating overnight at 4°C in rabbit polyclonal anti-Trx2 (1:250, Santa Cruz, sc-50336), rabbit polyclonal anti-Prx3 (1:1,000, Thermo Fisher Scientific, LF-PA0030), rabbit polyclonal anti-TrxR2 (1:1,000, Abcam, ab58445), rabbit polyclonal anti-ASK1 (1:500, Santa Cruz, sc-7931), rabbit polyclonal anti-pASK1 (1:1,000, Cell Signaling, 3765), rabbit polyclonal anti-Bax (1:1,000, Santa Cruz, sc-493), mouse monoclonal anti-Bak (1:1,000, EMD Millipore, AM03) or rabbit polyclonal anti-β-actin (1:1,000, Sigma Aldrich, A2066). Membranes were then incubated with anti-rabbit or anti-mouse (1:5,000, Southern Biotechnology) HRP-conjugated secondary antibodies and immune complexes were detected by chemiluminescence captured and analyzed on a UVP bioimaging system (Upland, CA). Semi-quantitative analyses of immunoblots were performed using Image Studio (LI-COR).

Quantitative Real-Time PCR (qPCR)

RNA was isolated using the SV Total RNA Isolation System (Promega). cDNA was synthesized from samples with an RNA integrity number of 8.0 or greater evaluated with a 2100 Bioanalyzer (Agilent Technologies). Primers and probes for qPCR were designed for human Prx3, Trx2, TrxR2 and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) using Beacon Designer 7.91 (Premier Biosoftware) (S1 Table). As previously described [31], primers (900 nM) and probes (250 nM) were diluted in 2X Absolute Blue master mix (Thermo Fisher Scientific) and assayed using a 7500 Real Time PCR System (ABI). Standard MIQE guidelines including internal primer validation through mass normalization, assessment of genomic DNA contamination, and assay efficiency were performed [32].

Mitochondrial Mass

To quantify variation in mitochondrial number as cells are cultured in hyperoxia, DNA was isolated from A549 over a four day hyperoxic timecourse. Phenol/chloroform isolated DNA was analyzed by real-time PCR using commercially available probes designed against the D-
loop region of mitochondrial DNA and the COXI mitochondrial gene (Fisher Scientific). Input template was mass normalized and mitochondrial Ct values were normalized to the corresponding Ct values for β-2-microglobulin (β2M), a nuclear DNA target. Primers and probes for β2M were designed to only amplify genomic DNA (S2 Table).

Redox Immunoblots
For Trx2 redox status, cells were lysed in 10% ice-cold trichloroacetic acid, washed in acetone, and protein pellets were resuspended in 20 mM Tris-HCl (pH 8.0) containing 15 mM AMS (4-acetoamido-4’-maleimidylstilbene-2,2’-disulphonic acid). Following AMS labeling, lysates were diluted in non-reducing Laemmli buffer and subjected to SDS-PAGE/immunoblot [33]. Trx2 redox potential (Eh) was determined using the Nernst equation with E0 = -330 mV for Trx2 at pH 7.6 and 25˚C [34]. For Prx3 analysis, cells were lysed in 100 mM N-ethylmaleimide (NEM) alkylation buffer supplemented with 10 μg/mL catalase to label and retain reduced monomers for non-reducing SDS-PAGE/immunoblot analysis [35].

Thioredoxin Reductase Activity Assay
For TrxR2 activity, a commercially available insulin reduction assay was utilized (Cayman Chemical). Cells were harvested in assay buffer (0.1 M NaPO4, 5 mM EDTA, 0.1% Triton X-100, 1% protease inhibitor cocktail (Sigma Aldrich), 1% phosphatase inhibitor cocktails 2 and 3 (Sigma Aldrich), and 0.1 mM PMSF) and rotated for 2 hours at 4˚C. Lysates were then spun at 10,000 rpm for 15 minutes at 4˚C. Supernatants were collected and protein concentration was determined by BCA. Reductase activity was measured in a 96-well plate according to manufacturer’s instructions. Absorbance was measured at 412nm using a Spectramax M5 microplate reader.

ShRNA Lentiviral Delivery
ShRNA sequences targeting human Trx2 and Prx3 as well as a non-targeting control were designed using BLOCK-iT RNAi Designer software from Thermo Fisher Scientific (S3 Table) and were cloned into the pLVX-shRNA2 (Clontech, Mountain View, CA). Following the manufacturer’s instructions for the Lenti-X system, Lenti-X 293T cells were transfected with pLVX-shRNA2 and HTX packaging mix to produce ≥2.5x10^8 IFU/mL as determined by qPCR. Cells were seeded in 6-well dishes and transduced with 0.5mL viral media supplemented with 8 μg/mL polybrene for 6 hours. Transduction efficiency after 48 hours was ≥85% by flow cytometry for ZsGreen1.

Statistical Analyses
Values represent mean ± standard deviation of biological replicates. Group means were compared by 1-way ANOVA using Bonferroni’s post hoc test with GraphPad Prism 5 (GraphPad Software). Statistical significance was defined as P ≤ 0.05.

Results
Generation of Mitochondrial Oxidants during Hyperoxic Injury
MitoSOX was used as an indicator of mitochondrial oxidant generation during hyperoxic culture [36, 37]. Time-dependent increases in MitoSOX signal intensity were detected in A549 lung epithelial cells cultured in 95% oxygen (Fig 1A and 1B). Cell death following hyperoxia was quantified using the cell-impermeable fluorescent dye, TO-PRO-3. TO-PRO-3 positive cells were considered dead while debris was excluded from analysis (S1 Fig). Time-dependent increases in cell death were observed over four days of hyperoxia which culminated in an
11-fold increase in cell death after four days (Fig 1C). To determine if detoxification of mitochondrial superoxide alleviated hyperoxic cell death, additional viability experiments were conducted during supplementation with the mitochondrial-targeted superoxide scavenger, MitoTEMPO. Cells simultaneously treated MitoTEMPO and hyperoxia had significantly reduced MitoSOX signal intensity and decreased cell death (Fig 1D and 1E). This data suggests a crucial role for mitochondrial oxidation in hyperoxic cell death.

Hyperoxic Modulation of Trx2 and Prx3 Expression and Activity

Hydrogen peroxide accumulation results from dismutation of superoxide by SOD2 in the mitochondrial matrix [38]. Therefore, we hypothesized that the expression and redox state of Prx3, Trx2, and TrxR2 may be altered as these redox enzymes function as a system to scavenge mitochondrial hydrogen peroxide. Transcript and protein expression of these genes were examined in two human lung epithelial cell lines, A549 and H1299. Although Prx3 gene expression decreased by approximately 50% in both cell lines, surprisingly, Trx2 expression increased nearly 10-fold in hyperoxia (Fig 2A and 2B). This coincided with a significant, albeit smaller, increase in TrxR2 expression (Fig 2C). Similar changes in Prx3, Trx2, and TrxR2 protein expression in both cell lines were detected by immunoblot (Fig 3A and 3B) and quantified (S2 Fig).
One simple explanation for increased MitoSOX red fluorescence intensity and upregulation of Trx2 and TrxR2 could be attributed to increased mitochondrial mass in response to extended hyperoxic culture [39]. To investigate this possibility, mitochondrial and nuclear DNA were isolated from A549 cells over four days of culture in hyperoxia. DNA was analyzed by real-time PCR using probes designed against two regions of mitochondrial DNA (mtDNA): cytochrome C oxidase 1 (COX1) and the control region (D-Loop) [40]. A primer and probe set were designed to amplify genomic DNA of the β-2-microglobulin (β2M) gene. MtDNA Ct values were normalized to corresponding β2M Ct values to derive mitochondrial:nuclear (mito:nuc) ratios for each sample. As a control experiment validating this method, treatment with dideoxycytidine or ethidium bromide expectedly decreased mito:nuc ratio determined by amplifying either D-Loop or COX1 (S3 Fig). No significant changes in mito:nuc ratio for either of the two mitochondrial genes were observed over the course of the hyperoxic exposure (Fig 4A and 4B). These data suggest that hyperoxic upregulation of mitochondrial thioredoxins and increased MitoSOX red fluorescence signal intensity are the consequence of a cellular response to increased production of mitochondrial oxidants and are not due to changes in mitochondrial number.

The oxidation state of the catalytic cysteines in Prx3 and Trx2 was monitored by differential thiol alkylation followed by SDS-PAGE. For Trx2 detection, free thiols were labeled with AMS, which causes a mass shift in the reduced form (S4A Fig) [22, 34]. As expected, Trx2 was predominantly reduced under control conditions and became oxidized after 4 days of hyperoxic culture (Fig 5A). Using the Nernst equation [34], Trx2 redox potential (Eh) was significantly
decreased during hyperoxia (Fig 5B). Oxidized Prx3 dimers were stabilized by alkylation of free thiols with NEM, and detection of Prx3 monomers and dimers under non-reducing conditions (S4B Fig) [35]. Prx3 oxidation is detected after 2 days of hyperoxia, which can be expected based on the very fast kinetic rate for the neutralization of hydrogen peroxide by peroxiredoxins (Fig 5C and 5D) [17, 41]. It is important to note that these data do not conflict with Prx3 expression as anti-peroxiredoxin antibodies are thought to have differential reactivity with oxidized and reduced forms [35].

Trx2 Prevents Hyperoxia-Induced Apoptotic Signaling

Pharmacologic and genetic approaches were used to determine if inhibition of Trx2 and/or Prx3 activity augmented hyperoxic mitochondrial injuries. Auranofin (AFN), a thioredoxin reductase inhibitor, is known to enter mitochondria, causing Prx3 oxidation (presumably via inhibition of Trx2 redox cycling) and MPTP activation [35, 42, 43]. As expected, AFN exhibited dose-dependent TrxR inhibition in A549 cells (Fig 6A). Culture in 2.5 μM AFN inhibited 91% of TrxR activity. Control cells cultured with AFN in room air had significantly increased MitoSOX red fluorescence intensity. Hyperoxic treatment resulted in more robust fluorescent signal which was not further exacerbated by AFN (Fig 6B). However, AFN supplementation augmented hyperoxic-dependent cell death (Fig 6C). AFN does not have specificity for TrxR2 alone; rather, it inhibits TrxR1 as well. As such, AFN-mediated cell death in the absence of increased MitoSOX red fluorescence may indeed be explained by TrxR1, and not TrxR2, inhibition. Since cytosolic Trx1 is known to sensitize cells to hyperoxic damage [31], a second set of experiments was conducted to genetically target Trx2 and Prx3 via RNAi knockdown. Cells were transduced with lentivirus expressing a non-targeting control or Trx2 and Prx3 targeting shRNAs. ShRNA delivery resulted in knockdown of the specific target without altering expression of the other key mitochondrial redox enzymes (Fig 6D). Knockdown of either Trx2 or Prx3 caused increased MitoSOX red fluorescence intensity in control cells and had a similar effect during hyperoxic culture (Fig 6E). Only knockdown of Trx2 caused increased hyperoxic-induced cell death (Fig 6F).

Based on the results of our viability experiments with Trx2 shRNA treatment during hyperoxia, we hypothesized that Trx2 knockdown may cause MPTP activation [23] and used TMRE as an indicator of mitochondrial membrane potential (ΔΨm). Hyperoxic culture resulted in

Fig 4. Hyperoxia does not alter mitochondrial mass. Ratio of mitochondrial:nuclear Ct values for (A) D-Loop and (B) COX1 after normalization to β2M quantified by qPCR in A549 during hyperoxic culture. Data are expressed as mean ± standard deviation of 3 biological replicates analyzed by one-way ANOVA. doi:10.1371/journal.pone.0168777.g004
mitochondrial hyperpolarization (as opposed to depolarization and subsequent MPTP opening), indicated by increased TMRE signal intensity (Fig 7A). To demonstrate specificity, TMRE signal was ablated after incubation for 15 minutes with the proton ionophore, FCCP (carbonyl cyanide 4-(trifluoromethoxy) phenylhydrazone), following hyperoxic culture (Fig 7A) [44]. However, mitochondrial hyperpolarization is associated with mitochondrial hypertrophy, a hallmark of hyperoxic injury [45]. Knockdown of both Trx2 and Prx3 caused increased mitochondrial hyperpolarization in A549 cells cultured in room air and hyperoxia (Fig 7B).

Fig 5. Trx2 and Prx3 oxidation during hyperoxia. (A,C) Differential Trx2 and Prx3 thiol labeling by AMS and NEM respectively, and (B,D) representative detection by SDS-PAGE/immunoblot in A549 cells after treatment with hyperoxia. Images are representative of 3–4 independent biological replicates.

doi:10.1371/journal.pone.0168777.g005
We also hypothesized that loss of Trx2 may cause susceptibility through loss of ASK1 inhibition [26, 27, 46]. Cells cultured in hyperoxia had increased ASK1 phosphorylation at Thr845, which coincided with increased expression of pro-apoptotic Bax and Bak and reduced expression of anti-apoptotic Bcl-X\textsubscript{L} and Mcl-1 (Fig 8A). Knockdown of Trx2 in hyperoxia increased ASK1 phosphorylation with no change in expression of anti- and pro-apoptotic Bcl-2 family proteins (Fig 8B).

**Discussion**

Apoptosis of alveolar epithelial cells is considered an important contributor to BPD pathogenesis [47]. Previous work has focused on molecular signals both converging on and being propagated by mitochondria during hyperoxic cell death. Budinger et al. performed a comparative study deleting genes activating intrinsic (Bax, Bak, Bim, Puma, Noxa) and extrinsic (FADD, Bid) apoptotic signaling [48]. Only disruption of Bax and Bak improved survival of adult mice and mouse embryonic fibroblasts subjected to 95% oxygen. Surprisingly, single deletion of BH3-only (Bim, Puma, and Noxa) direct activators of Bax and Bak did not have any effect. It is...
possible that BH3-only pathways resulting in activation of Bax and Bak during hyperoxia are redundant and/or converge to repress anti-apoptotic Bcl-2 family proteins such as Bcl-X\textsubscript{L}, Mcl-1, and Bcl-2 [49]. Since intrinsic apoptotic signaling via Bcl-2 family proteins is an important determinant of hyperoxic cell death, we hypothesized that mitochondrial oxidoreductases may serve as a signaling intermediate between intracellular oxidants generated during hyperoxia and injury/death pathways. Our data provide a unique contribution considering how Trx2 and Prx3 function to facilitate electron flux for detoxification of mitochondrial oxidants and regulation of injury signaling during hyperoxic exposure.

In agreement with previous reports, we demonstrate that mtROS directly contribute to oxygen-induced cell death [9, 10]. Continuous MitoTEMPO treatment was able to detoxify mitochondrial superoxide radical generation which correlated with significantly reduced hyperoxic cell death. Superoxide radical was detected with MitoSOX via flow cytometry, which increased emitted red fluorescence by generation of the two-electron oxidation product, 2-hydroxymitoethidium, formed from MitoSOX interactions with superoxide radical [50]. MitoSOX carries a net positive charge and preferentially reacts with superoxide to form 2-hydroxymitoethidium; however, it is possible that a minor quantity of MitoSOX is oxidized by other routes. Reactions with single electron oxidants, such as hydrogen peroxide and peroxidases, result in non-specific oxidation of MitoSOX and produce mitohydroethidium, which also generates red fluorescence [51]. The fluorescent spectra of 2-hydroxymitoethidium, the superoxide specific product, and mitohydroethidium overlap. For this reason, in the context of this study, MitoSOX reactivity was, in large part, sensitive to hyperoxic generation of mitochondrial superoxide.

Although mitochondrial hyperpolarization and mtROS generation are associated with MPTP activation [45], MPTP activation may not be required for hyperoxia-induced cell death. Currently, cyclophilin D is the only defined regulatory component of the MPTP and mice deficient in cyclophilin D had similar TUNEL-staining, lung pathology, and survival rates as wild-type counterparts during hyperoxic injury [48]. ShRNA knockdown of either Trx2 or Prx3 resulted in increased mtROS and mitochondrial hyperpolarization during culture in both

![Fig 7. Hyperoxia-induced mitochondrial hyperpolarization.](image)

(A) Fold-change in TMRE fluorescence intensity of A549 cells cultured in hyperoxia in the absence or presence of 0.5 \( \mu \text{M} \) FCCP. (B) TMRE fluorescence intensity after 3 days hyperoxic culture following lentiviral transduction of NT, Trx2, or Prx3 shRNAs in A549 cells. Data are expressed as mean ± standard deviation of 3 biological replicates analyzed by one-way ANOVA. Statistical significance was defined as **\( p < 0.01 \), and †\( p < 0.001 \).

doi:10.1371/journal.pone.0168777.g007
room air and hyperoxia. It is unknown if or how mtROS and mitochondrial hyperpolarization are related during hyperoxic injury but both are likely influenced by bioenergetic changes. For example, less ATP synthesized by OXPHOS during hyperoxic exposure may promote mitochondrial hyperpolarization [53, 54].

Trx2 activity, and not Prx3, was required for cytoprotection from hyperoxic cell death. Reduced Trx2 binds to the N-terminal of ASK1, preventing serine/threonine kinase activity [26]. Our data demonstrate that ASK1 phosphorylation increased during hyperoxic culture and was exacerbated by Trx2 knockdown. As a MAP kinase kinase kinase, ASK1 signaling culminates in JNK and p38 activation, both of which are associated with hyperoxic injury [55–57]. Furthermore, ASK1-deficient mice had reduced lung injury when treated with large tidal mechanical ventilation and hyperoxia [58]. Inhibitory Trx2 binding to ASK1 can be relieved by overt thioredoxin oxidation or displacement via TXNIP binding [28, 59]. Although pulmonary TXNIP may inhibit alveolar growth [60], we did not detect mitochondrial localization of

---

**Fig 8. Trx2 inhibits hyperoxic phosphorylation of ASK1.** Expression of pro-apoptotic proteins by SDS-PAGE/immunoblot in A549 cells during (A) hyperoxic culture. (B) Immunoblots of lysates from A549 cultured in hyperoxia for two days following lentiviral delivery of NT, Trx2, or Prx3 shRNAs. Images are representative of 3 independent biological replicates.

doi:10.1371/journal.pone.0168777.g008
TXNIP in A549 cells during hyperoxia (data not shown). ASK1 phosphorylation can also be stimulated by TRAF2 and TRAF6 binding [61]. However, oxidative stimulation may also be required to promote TRAF2 and TRAF6 binding, ASK1 dimerization, and autophosphorylation at Thr845. Trx2 cytoprotection may also involve regulation of Bcl-2 family proteins. Knockdown of Trx2 in DT40 cells caused loss of anti-apoptotic Bcl-X<sub>L</sub> but this was not dependent on oxidoreductase activity [62]. Modulation of Bcl-X<sub>L</sub> levels is associated with injury outcomes in hyperoxia [13–16], but we did not detect Trx2-dependent changes in Bcl-X<sub>L</sub> expression (Fig 8B). It is possible that ASK1 modulation may serve as a mechanistic link between Trx2 and the Bcl-2 family proteins since Bcl-2 is phosphorylated by the ASK1:JNK MAPK signaling axis [63]. This leaves the possibility that post-translational modifications or localization changes in Bcl-2 family proteins is critical for Trx2-mediated cytoprotection from hyperoxic cell death.

Independent of precise apoptotic mechanisms, our data support that Prx3 acts as an oxidant sensor to modulator Trx2 activity. The reactivity of MitoSOX with superoxide radical is likely short-lived as it is dismutated to hydrogen peroxide by SOD2. Hydrogen peroxide can initiate redox-dependent signaling changes through reversible oxidation of reactive protein thiols [64]. Although cysteine oxidation by hydrogen peroxide is thermodynamically favorable, direct oxidation of protein thiols is unlikely to occur as the kinetic rate is very slow (k ~ 1–10 M<sup>-1</sup>s<sup>-1</sup>) with the exemption of catalytic thiols of dedicated redox enzymes including catalase, peroxiredoxins, glutathione peroxidases, and ascorbate peroxidases [17, 41, 65]. Prx3 reacts with approximately 90% of mitochondrial peroxides due to abundance and kinetic activity [17]. In contrast to the high buffering capacity of Prx3, Trx2 is present at much lower concentrations and is therefore a limiting factor more likely to serve as a threshold to initiate redox-dependent signaling. As shown in Fig 9, under control conditions, reduction of molecular oxygen by OXPHOS results in formation of mtROS which may be comprised of superoxide radical, hydrogen peroxide, and/or hydroxyl radical. Prx3 reduces mitochondrial peroxide and is recycled by Trx2 and TrxR2 with electrons being ultimately donated from NADPH. Therefore, Trx2 is primarily in a reduced state which exhibits selective inhibition of ASK1. During hyperoxic exposure, accumulation of mtROS and oxidation of Prx3 increases Trx2:TrxR2 redox cycling which likely exhausts reducing equivalents of NADPH [41]. Hyperoxic depletion of NADPH may also explain why overexpression of Trx2 did not reduce oxygen-induced cell death (S5 Fig). Oxidation of Trx2 relieves ASK1 inhibition, resulting in subsequent ASK1 phosphorylation and activation of cell death. It is also possible that other Trx2 substrates serve as mediators between Trx2 oxidation and ASK1 phosphorylation. Since oxidized Prx3 is required to relieve Trx2 anti-apoptotic repression, this scheme describes why limiting either Prx3 or Trx2 results in accumulation of mitochondrial peroxide while inhibition of only Trx2 promotes hyperoxic cell death. Based on this mechanism, we propose that hyperoxic
upregulation of Trx2 and TrxR2 is an adaptive response to prevent accumulation of oxidized Prx3 as the initiating damage signal. Although Wnt may influence TrxR2 expression [66], no regulatory elements in the Trx2 promoter have been described and this is an important trajectory of future research.

Since Prx3 and Trx2 do not exclusively metabolize mitochondrial peroxides, it is important to consider how mitochondrial glutathione peroxidases (Gpx) function in response to hyperoxic injury. It is likely that peroxide metabolism and protein glutathionylation function in parallel in the mitochondria since depletion of glutathione results in Trx2 oxidation [67]. Loss of Gpx1 did not increase mortality in adult mice treated with hyperoxia, further supporting a redundant functional link between thioredoxin- and glutathione-dependent systems [68]. However, Trx2-deficient mice are not viable, marked by apoptosis beginning at E9.5, a time coinciding with a metabolic shift to OXPHOS and likely increase in mtROS generation [69].

Exposure of newborn mice to short-term hyperoxia followed by recovery in room air recapitulates many BPD pathologies including impaired alveolar and vascular growth with restrictive lung disease and early mortality attributed to pulmonary hypertension [5, 70–72]. A possible explanation for these primary and subsequent phenotypes is that neonatal hyperoxia reduces numbers of alveolar epithelial AT2 cells [4–6], which are known to serve as progenitor cells during alveologenesis and alveolar repair [73]. Although it is possible that Trx2 mediates AT2 cell death in vivo, it is unlikely that hyperoxic depletion of AT2 cells in the perinatal lung can be explained exclusively by cell death. Yee et al. report that hyperoxia stimulates expression of genetic markers indicative of alveologenesis and that AT2 cell numbers slowly diminish during the recovery phase [6]. This exacerbated expansion of AT2 cells may be due to prolonged or enhanced activation of oxygen-dependent signaling pathways regulating perinatal alveologenesis while transitioning to a more oxidative atmospheric environment outside the womb. Therefore, altered AT2 programming may also contribute to BPD pathologies due to accumulation of mitochondrial oxidants in the alveolar epithelium due to tissue hypoxia, hyperoxic exposure, and recovery to room air. While hyperoxic injury has direct translational implications in BPD, production of mtROS is an important component of oxidative lung diseases including acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) [74, 75]. It is likely that Trx2 and Prx3 are similarly involved in maintenance of mtROS and apoptotic signaling during ALI and ARDS which may mediate inflammatory signaling via mitochondrial release of damage-associated molecular patterns (DAMPs) [76].

Taken together, our data support that Trx2 activity is cytoprotective against hyperoxic injury; however, these results obtained from adenocarcinoma cells may not accurately recapitulate molecular physiologies in vivo due to redox and metabolic imbalances in cell culture models [77, 78], and altered expression of Prx3, Trx2, or TrxR2 which will influence electron flux [79]. Consistent with such differences, no changes in expression of Prx3, Trx2, or TrxR2 were detected in lungs of oxygen-exposed newborn mice (S6 Fig). Despite these preliminary findings, we still speculate that future studies should consider accumulation of mitochondrial peroxides and altered redox signaling as molecular mechanisms involved in AT2 programming during lung development and oxidative lung injuries. In summary, these data support that detoxification of mitochondrial oxidants was uncoupled from cytoprotection which we hypothesize occurs through an ASK1 thiol switch regulated by Trx2 oxidation. Oxidized Prx3 accumulates during hyperoxic exposure and serve as the initiating event by exhausting redox cycling of Trx2/TrxR2, thus relieving Trx2-dependent inhibition of ASK1 phosphorylation. Prx3, Trx2, and TrxR2 function as a system to detoxify mitochondrial peroxides during hyperoxic injury although it is likely that their activities are coordinated with catalase, manganese SOD, and Gpx1. Investigation of coordination between these pathways may reconcile conflicting data from transgenic and knockout antioxidant enzyme mouse models [80, 81].
Conclusions

We conclude that Prx3 and Trx2 comprise an adaptive system to sense changes in atmospheric oxygen tension and influence cellular injury responses through both detoxification of mitochondrial oxidants and regulation of mitochondrial redox-dependent signaling.

Supporting Information

S1 Fig. Flow cytometric analysis of hyperoxic cell death. A549 cells were cultured in room air or hyperoxia for four days. Viability was measured via flow cytometry by using TOPRO-3 as a marker of cell death (percentages indicate upper-quadrant distribution of cells).

S2 Fig. Protein quantification of mitochondrial redoxins Prx3, Trx2, and TrxR2 during hyperoxia. Densitometric quantification of SDS-PAGE/immunoblots of oxygen-treated A549 and H1299 cell lysates probed for (A) Prx3, (B) Trx2, and (C) TrxR2 normalized to β-actin as a loading. Data are expressed as mean ± standard deviation of 3 biological replicates analyzed by one-way ANOVA. Statistical significance was defined as *p<0.05, **p<0.01, and †p<0.001.

S3 Fig. Decreased mitochondrial mass following ddC or EtBr treatment. Ratio of mitochondrial:nuclear Ct values for D-Loop and COX1 after normalization to β2M quantified by qPCR in A549 cells following 5 days treatment with 20 μM dideoxycytidine (ddC) or 75 ng/mL ethidium bromide (EtBr). Data are expressed as mean ± standard deviation of 3 biological replicates analyzed by one-way ANOVA. Statistical significance was defined as **p<0.01 and †p<0.001.

S4 Fig. Detection of Trx2 and Prx3 oxidation. Differential (A) Trx2 and (B) Prx3 thiol labeling by AMS and NEM respectively.

S5 Fig. Trx2 overexpression does not prevent hyperoxic cell death. A C-terminal flag epitope was introduced by PCR of Trx2 cDNA (NM_012473), ligated into the doxycycline-inducible pBIG2i vector, and stably transfected into H1299 cells. (A) SDS-PAGE/immunoblot of H1299 cell lysates for the Trx2-flag transgene 24 hours following culture in 2μg/mL doxycycline (DOX). (B) Immunocytochemistry and mitochondrial co-localization of Trx2-flag. (C) Viability of two H1299+Trx2-flag clones cultured in absence or presence of DOX and cultured in hyperoxia for 3 days. Data are expressed as mean ± standard deviation and analyzed by one-way ANOVA.

S6 Fig. Oxygen-dependent pulmonary expression of Prx3, Trx2, and TrxR2. C57Bl/6j newborn litters (PND<0.5) were randomly placed in 85% oxygen or room air for the first seven days of life. After seven days, room air or hyperoxic lungs were analyzed by qPCR using the following Taqman probes: Txn2 (MM0044931_M1), Prdx3 (MM00545848_M1), Txnrd2 (MM00496766_M1), and HPRT (MM01545399_M1). Data are expressed as mean ± standard deviation of 3–4 biological replicates analyzed by student’s t-test.

S1 Table. qPCR primer and probe sequences. qPCR primers and 6-carboxyfluorescein (FAM)-labeled probe sequences targeting human Txn2, Prx2, TrxR2, and GAPDH.
S2 Table. qPCR primer and probe sequences for quantifying mitochondrial mass. Catalog numbers and sequence for qPCR primers and 4,7,2-tricholo-7-phenyl-carboxyfluorescein (VIC)-labeled probe sequences targeting human D-Loop, COX1, and β-2-microglobulin. (DOCX)

S3 Table. ShRNA sequences. Non-targeting or human Trx2- and Prx3-targeting shRNA sequences (sense-loop-antisense). (DOCX)

Acknowledgments
We would like to thank the Imaging, Molecular Biology, and Flow Cytometry Cores at Sanford Research for technical assistance.

Author Contributions
Conceptualization: BJF PFV.
Formal analysis: BJF PFV.
Funding acquisition: PFV.
Investigation: BJF DRD BKT RRW MJF MLB PFV.
Methodology: BJF PFV.
Project administration: PFV.
Resources: PFV.
Supervision: PFV.
Validation: BJF PFV.
Visualization: BJF PFV.
Writing – original draft: BJF PFV.
Writing – review & editing: BJF PFV.

References
1. Asikainen TM, White CW. Pulmonary antioxidant defenses in the preterm newborn with respiratory distress and bronchopulmonary dysplasia in evolution: implications for antioxidant therapy. Antioxidants & redox signaling. 2004; 6(1):155–67.
2. Mirza H, Ziegler J, Ford S, Padbury J, Tucker R, Laptok A. Pulmonary hypertension in preterm infants: prevalence and association with bronchopulmonary dysplasia. The Journal of pediatrics. 2014; 165(5):909–14 e1. doi: 10.1016/j.jpeds.2014.07.040 PMID: 25189821
3. Mourani PM, Sontag MK, Younoszai A, Miller JI, Kinsella JP, Baker CD, et al. Early pulmonary vascular disease in preterm infants at risk for bronchopulmonary dysplasia. American journal of respiratory and critical care medicine. 2015; 191(1):87–95. doi: 10.1164/rccm.201409-1594OC PMID: 25389562
4. McGrath-Morrow SA, Stahl J. Apoptosis in neonatal murine lung exposed to hyperoxia. American journal of respiratory and cell molecular biology. 2001; 25(2):150–5. doi: 10.1165/ajrcmb.25.2.4362 PMID: 11509323
5. Yee M, Vitello PF, Roper JM, Staversky RJ, Wright TW, McGrath-Morrow SA, et al. Type II epithelial cells are critical target for hyperoxia-mediated impairment of postnatal lung development. American journal of physiology Lung cellular and molecular physiology. 2006; 291(5):L1101–11. doi: 10.1152/ajplung.00126.2006 PMID: 16861382
6. Yee M, Buczynski BW, O'Reilly MA. Neonatal hyperoxia stimulates the expansion of alveolar epithelial type II cells. American journal of respiratory cell and molecular biology. 2014; 50(4):757–66. PubMed Central PMCID: PMC4068992. doi: 10.1165/rcmb.2013-0207OC PMID: 24188066

7. Hutten MC, Wolfs TG, Kramer BW. Can the preterm lung recover from perinatal stress? Molecular and cellular pediatrics. 2016; 3(1):15. PubMed Central PMCID: PMC4830776. doi: 10.1186/s40348-016-0043-9 PMID: 27075524

8. Castillo RL, Carrasco Loza R, Romero-Dapueto C. Pathophysiological Approaches of Acute Respiratory Distress syndrome: Novel Bases for Study of Lung Injury. The open respiratory medicine journal. 2015; 9:83–91. PubMed Central PMCID: PMC4541465. doi: 10.2174/187430640150901010083 PMID: 26312099

9. Li J, Gao X, Qian M, Eaton JW. Mitochondrial metabolism underlies hyperoxic cell damage. Free radical biology & medicine. 2004; 36(11):1460–70.

10. Budinger GR, Tso M, McClintock DS, Dean DA, Sznajder JI, Chandel NS. Hyperoxia-induced apoptosis does not require mitochondrial reactive oxygen species and is regulated by Bcl-2 proteins. The Journal of biological chemistry. 2002; 277(18):15654–60. doi: 10.1074/jbc.M109317200 PMID: 11877388

11. Tomanek L. Proteomic responses to environmentally induced oxidative stress. The Journal of experimental biology. 2015; 218(Pt 12):1867–79. doi: 10.1242/jeb.116475 PMID: 26085664

12. Buccellato LJ, Tso M, Akinci OI, Chandel NS, Budinger GR. Reactive oxygen species are required for hyperoxia-induced Bax activation and cell death in alveolar epithelial cells. The Journal of biological chemistry. 2004; 279(8):6753–60. doi: 10.1074/jbc.M310145200 PMID: 14625274

13. Vitiello PF, Staversky RJ, Keng PC, O’Reilly MA. PUMA inactivation protects against oxidative stress through p21/Bcl-XL inhibition of bax death. Free radical biology & medicine. 2008; 44(3):367–74. PubMed Central PMCID: PMC2276618.

14. Staversky RJ, Vitiello PF, Yee M, Callahan LM, Dean DA, O’Reilly MA. Epithelial ablation of Bcl-XL increases sensitivity to oxygen without disrupting lung development. American journal of respiratory cell and molecular biology. 2010; 43(3):376–85. PubMed Central PMCID: PMC2933553. doi: 10.1165/rcmb.2009-0165OC PMID: 19880821

15. Vitiello PF, Staversky RJ, Gehcen SC, Johnston CJ, Finkelstein JN, Wright TW, et al. p21Cip1 protection against hyperoxia requires Bcl-XL and is uncoupled from its ability to suppress growth. The American journal of pathology. 2006; 168(6):1838–47. PubMed Central PMCID: PMC1606637. doi: 10.2353/ajpath.2006.051162 PMID: 16723699

16. Vitiello PF, Wu YC, Staversky RJ, O’Reilly MA. p21(Cip1) protects against oxidative stress by suppressing ER-dependent activation of mitochondrial death pathways. Free radical biology & medicine. 2009; 46(1):33–41. PubMed Central PMCID: PMC2631574.

17. Cox AG, Winterbourn CC, Hampton MB. Mitochondrial peroxiredoxin involvement in antioxidant defence and redox signalling. The Biochemical journal. 2010; 425(2):313–25.

18. Cox AG, Peskin AV, Paton LN, Winterbourn CC, Hampton MB. Redox potential and peroxide reactivity of human peroxiredoxin 3. Biochemistry. 2009; 48(27):6495–501. doi: 10.1021/bi900558g PMID: 19462976

19. Hall A, Karplus PA, Poole LB. Typical 2-Cys peroxiredoxins—structures, mechanisms and functions. The FEBS journal. 2009; 276(9):2469–77. PubMed Central PMCID: PMC27477500. doi: 10.1111/j.1742-4688.2009.06695.x PMID: 19476488

20. Chen Y, Cai J, Murphy TJ, Jones DP. Overexpressed human mitochondrial thioredoxin confers resistance to oxidant-induced apoptosis in human osteosarcoma cells. The Journal of biological chemistry. 2002; 277(36):33242–8. doi: 10.1074/jbc.M202026200 PMID: 12032145

21. Hansen JM, Zhang H, Jones DP. Mitochondrial thioredoxin-2 has a key role in determining tumor necrosis factor-alpha-induced reactive oxygen species generation, NF-κappaB activation, and apoptosis. Toxicological sciences: an official journal of the Society of Toxicology. 2006; 91(2):643–50.

22. Damdimopoulos AE, Miranda-Vizuet A, Pelto-Huikko M, Gustafsson JA, Spyrou G. Human mitochondrial thioredoxin. Involvement in mitochondrial membrane potential and cell death. The Journal of biological chemistry. 2002; 277(36):33249–57. doi: 10.1074/jbc.M203036200 PMID: 12080052

23. He M, Cai J, Go YM, Johnson JM, Martin WD, Hansen JM, et al. Identification of thioredoxin-2 as a regulator of the mitochondrial permeability transition. Toxicological sciences: an official journal of the Society of Toxicology. 2008; 105(1):44–50. PubMed Central PMCID: PMC2734306.

24. Chen FQ, Zheng HW, Schacht J, Sha SH. Mitochondrial peroxiredoxin 3 regulates sensory cell survival in the cochlea. PloS one. 2013; 8(4):e61999. PubMed Central PMCID: PMC3633911. doi: 10.1371/journal.pone.0061999 PMID: 23626763

25. Hattori F, Murayama N, Noshita T, Oikawa S. Mitochondrial peroxiredoxin-3 protects hippocampal neurons from excitotoxic injury in vivo. Journal of neurochemistry. 2003; 86(4):860–8. PMID: 12887684
26. Zhang R, Al-Lamki R, Bai L, Streb JW, Miano JM, Bradley J, et al. Thioredoxin-2 inhibits mitochondria-located ASK1-mediated apoptosis in a JNK-independent manner. Circulation research. 2004; 94(11):1483–91. doi: 10.1161/01.RES.0000130525.37646.a7 PMID: 15117824

27. Huang Q, Zhou HJ, Zhang H, Huang Y, Hinojosa-Kirschenbaum F, Fan P, et al. Thioredoxin-2 inhibits mitochondrial reactive oxygen species generation and apoptosis stress kinase-1 activity to maintain cardiac function. Circulation. 2015; 131(12):1082–97. PubMed Central PMCID: PMC4374031. doi: 10.1161/CIRCULATIONAHA.114.012725 PMID: 25628390

28. Saxena G, Chen J, Shalev A. Intracellular shuttling and mitochondrial function of thioredoxin-interacting protein. The Journal of biological chemistry. 2010; 285(6):3997–4005. PubMed Central PMCID: PMC2823541. doi: 10.1074/jbc.M109.034421 PMID: 19959470

29. Giard DJ, Aaronson SA, Todaro GJ, Arinstein P, Kersey JH, Dosik H, et al. In vitro cultivation of human tumors: establishment of cell lines derived from a series of solid tumors. Journal of the National Cancer Institute. 1973; 51(5):1417–23. PMID: 4357758

30. Giaccone G, Battey J, Gazdar AF, Oie H, Moody TW. Neuromedin B is present in lung cancer cell lines. Cancer research. 1992; 52(9 Suppl):2732s–6s. PMID: 1563005

31. Saxena G, Chen J, Shalev A. Intracellular shuttling and mitochondrial function of thioredoxin-interacting protein. The Journal of biological chemistry. 2010; 285(6):3997–4005. PubMed Central PMCID: PMC2823541. doi: 10.1074/jbc.M109.034421 PMID: 19959470

32. Bustin SA, Benes V, Garson JA, Hellemans J, Huggett J, Kubista M, et al. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clinical chemistry. 2009; 55(4):611–22. doi: 10.1373/clinchem.2008.112797 PMID: 19246619

33. Halvey PJ, Watson WH, Hansen JM, Go YM, Samali A, Jones DP. Compartmental oxidation of thiol-disulphide redox couples during epidermal growth factor signalling. The Biochemical journal. 2005; 386(Pt 2):215–9. PubMed Central PMCID: PMC1134784. doi: 10.1042/BJ20041829 PMID: 15647005

34. Go YM, Jones DP. Thioredoxin redox western analysis. Current protocols in toxicology / editorial board, Mahin D Maines. 2009; Chapter 17:Unit17.2.

35. Cox AG, Winterbourn CC, Hampton MB. Measuring the redox state of cellular peroxiredoxins by immunoblotting. Methods in enzymology. 2010; 474:51–66. doi: 10.1016/S0076-6879(10)74004-0 PMID: 2069904

36. Robinson KM, Janes MS, Pehar M, Monette JS, Ross MF, Hagen TM, et al. Selective fluorescent imaging of superoxide in vivo using ethidium-based probes. Proceedings of the National Academy of Sciences of the United States of America. 2006; 103(41):15038–43. PubMed Central PMCID: PMC1586181. doi: 10.1073/pnas.0601945103 PMID: 17015830

37. Mukhopadhyay P, Rajesh M, Yoshihiro K, Hasko G, Pacher P. Simple quantitative detection of mitochondrial superoxide production in live cells. Biochemical and biophysical research communications. 2007; 358(1):203–8. PubMed Central PMCID: PMC2228267. doi: 10.1016/j.bbrc.2007.04.106 PMID: 17475217

38. Flynn JM, Melov S. SOD2 in mitochondrial dysfunction and neurodegeneration. Free radical biology & medicine. 2013; 62:4–12. PubMed Central PMCID: PMC3811078.

39. Resseguie EA, Staversky RJ, Brookes PS, O'Reilly MA. Hyperoxia activates ATM independent from mitochondrial ROS and dysfunction. Redox biology. 2015; 5:176–85. PubMed Central PMCID: PMC4430709. doi: 10.1016/j.redox.2015.04.012 PMID: 25967673

40. Phillips NR, Sprouse ML, Roby RK. Simultaneous quantification of mitochondrial DNA copy number and deletion ratio: a multiplex real-time PCR assay. Scientific reports. 2014; 4:3887. doi: 10.1038/srep03887 PMID: 24463429

41. Riemer J, Schwarzlander M, Conrad M, Herrmann JM. Thiol switches in mitochondria: operation and physiological relevance. Biological chemistry. 2015; 396(5):465–82. doi: 10.1515/hbz-2014-0293 PMID: 25720067

42. Brown KK, Cox AG, Hampton MB. Mitochondrial respiratory chain involvement in peroxiredoxin 3 oxidation by phenethyl isothiocyanate and auranofin. FEBS letters. 2010; 584(6):1257–62. doi: 10.1016/j.febslet.2010.02.042 PMID: 20176019

43. Rigobello MP, Scutari G, Boscolo R, Bindoli A. Induction of mitochondrial permeability transition by auranofin, a gold(I)-phosphine derivative. British journal of pharmacology. 2002; 136(8):1162–8. PubMed Central PMCID: PMC1573451. doi: 10.1038/sj.bjp.0704823 PMID: 12163349

44. Perry SW, Norman JP, Barbieri J, Brown EB, Gelbard HA. Mitochondrial membrane potential probes and the proton gradient: a practical usage guide. BioTechniques. 2011; 50(2):96–115. PubMed Central PMCID: PMC3115691. doi: 10.2144/000113610 PMID: 21486251

Mitochondrial Thioredoxin System in Hyperoxia

PLOS ONE | DOI:10.1371/journal.pone.0168777 January 3, 2017 18 / 20
Mitochondrial Thioredoxin System in Hyperoxia

45. Rasola A, Bernardi P. The mitochondrial permeability transition pore and its adaptive responses in tumor cells. Cell calcium. 2014; 56(6):437–45. PubMed Central PMCID: PMC4274314. doi: 10.1016/j.ceca.2014.10.003 PMID: 25454774

46. Lim PL, Liu J, Go ML, Boelsterli UA. The mitochondrial superoxide/thioredoxin-2/Ask1 signaling pathway is critically involved in troglitazone-induced cell injury to human hepatocytes. Toxicological sciences: an official journal of the Society of Toxicology. 2008; 101(2):341–9.

47. Del Riccio V, van Tuyl M, Post M. Apoptosis in lung development and neonatal lung injury. Pediatric research. 2004; 55(2):183–9. doi: 10.1203/01.PDR.0000103930.93849.B2 PMID: 14630991

48. Budinger GR, Mutlu GM, Urich D, Soberanes S, Buccellato LJ, Hawkins K, et al. Epithelial cell death is an important contributor to oxidant-mediated acute lung injury. American journal of respiratory and critical care medicine. 2011; 183(8):1043–54. PubMed Central PMCID: PMC3086743. doi: 10.1164/rccm.201002-0181OC PMID: 20955577

49. Czabotar PE, Lessene G, Strasser A, Adams JM. Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy. Nature reviews Molecular cell biology. 2014; 15(1):49–63. doi: 10.1038/nrm3722 PMID: 24355989

50. Kalyanaraman B, Darley-Usmar V, Davies KJ, Denny PA, Forman HJ, Grisham MB, et al. Measuring reactive oxygen and nitrogen species with fluorescent probes: challenges and limitations. Free radical biology & medicine. 2012; 52(1):1–6. PubMed Central PMCID: PMC3911769.

51. Robinson KM, Janes MS, Beckman JS. The selective detection of mitochondrial superoxide by live cell imaging. Nature protocols. 2008; 3(6):941–7. doi: 10.1038/nprot.2008.56 PMID: 18536642

52. Dikalova AE, Bikineyeva AT, Budzyn K, Nazarewicz RR, McCann L, Lewis W, et al. Therapeutic targeting of mitochondrial superoxide in hypertension. Circulation research. 2010; 107(1):106–16. PubMed Central PMCID: PMC2901409. doi: 10.1161/CIRCRESAHA.109.214601 PMID: 20448215

53. Das KC. Hyperoxia decreases glycolytic capacity, glycolytic reserve and oxidative phosphorylation in MLE-12 cells and inhibits complex I and II function, but not complex IV in isolated mouse lung mitochondria. PloS one. 2013; 8(9):e73358. PubMed Central PMCID: PMC3759456. doi: 10.1371/journal.pone.0073358 PMID: 24023862

54. Brand MD, Nicholls DG. Assessing mitochondrial dysfunction in cells. The Biochemical journal. 2011; 435(2):297–312. PubMed Central PMCID: PMC3076726. doi: 10.1042/BJ20110162 PMID: 21726199

55. Petrache I, Choi ME, Otterbein LE, Chin BY, Mantell LL, Horowitz S, et al. Mitogen-activated protein kinase pathway mediates hyperoxia-induced apoptosis in cultured macrophage cells. The American journal of physiology. 1999; 277(3 Pt 1):L589–95.

56. Li Z, Choo-Wing R, Sun H, Sureshbabu A, Sakurai R, Rehan VK, et al. A potential role of the JNK pathway in hyperoxia-induced cell death, myofibroblast transdifferentiation and TGF-beta1-mediated injury in the developing murine lung. BMC cell biology. 2011; 12:54. PubMed Central PMCID: PMC3266206. doi: 10.1186/1471-2121-12-54 PMID: 22172122

57. Li LF, Liao SK, Ko YS, Lee CH, Quinn DA. Hyperoxia increases ventilator-induced lung injury via mitogen-activated protein kinases: a prospective, controlled animal experiment. Critical care. 2007; 11(1):R25. PubMed Central PMCID: PMC2151853. doi: 10.1186/cc5704 PMID: 17316425

58. Makena PS, Gorantla VK, Ghosh MC, Beazwada L, Kandasamy K, Balazs L, et al. Deletion of apoptosis signal-regulating kinase-1 prevents ventilator-induced lung injury in mice. American journal of respiratory cell and molecular biology. 2012; 46(4):461–9. PubMed Central PMCID: PMC3359950. doi: 10.1186/1471-2121-12-54 PMID: 22052879

59. Sun HY, Hu YJ, Zhao XY, Zhong Y, Zeng LL, Chen XB, et al. Age-related changes in mitochondrial antioxidant enzyme Trx2 and TXNIP-Trx2-ASK1 signal pathways in the auditory cortex of a mimetic aging rat model: changes to Trx2 in the auditory cortex. The FEBS journal. 2015; 282(14):2758–74. doi: 10.1111/febs.13324 PMID: 25996168

60. Tippie TE, Welty SE, Nelin LD, Hansen JM, Rogers LK. Alterations of the thioredoxin system by hyperoxia: implications for alveolar development. American journal of respiratory cell and molecular biology. 2009; 41(5):612–9. PubMed Central PMCID: PMC2778167. doi: 10.1165/rcmb.2008-0224OC PMID: 19244220

61. Liu H, Nishiho H, Ichijo H, Kyriakis JM. Activation of apoptosis signal-regulating kinase 1 (ASK1) by tumor necrosis factor receptor-associated factor 2 requires prior dissociation of the ASK1 inhibitor thioredoxin. Molecular and cellular biology. 2000; 20(6):2198–208. PubMed Central PMCID: PMC110836. PMID: 10688666

62. Wang D, Masutani H, Oka S, Tanaka T, Yamauchi-Iwai Y, Nakamura H, et al. Control of mitochondrial outer membrane permeabilization and Bcl-xl levels by thioredoxin 2 in DT40 cells. The Journal of biological chemistry. 2006; 281(11):7384–91. doi: 10.1074/jbc.M509876200 PMID: 16407224
63. Yamamoto K, Ichijo H, Korsmeyer SJ. BCL-2 is phosphorylated and inactivated by an ASK1/Jun N-terminal protein kinase pathway normally activated at G(2)/M. Molecular and cellular biology. 1999; 19(12):8469–78. PubMed Central PMCID: PMC84954. PMID: 10567572

64. Sobotta MC, Liou W, Stocker S, Talwar D, Oehler M, Ruppert T, et al. Peroxiredoxin-2 and STAT3 form a redox relay for H2O2 signaling. Nature chemical biology. 2015; 11(1):64–70. doi: 10.1038/nchembio.1695 PMID: 25402766

65. Deponte M, Lillig CH. Enzymatic control of cysteiny1 thiol switches in proteins. Biological chemistry. 2015; 396(5):401–13. doi: 10.1515/hbz-2014-0280 PMID: 25581754

66. Ho YS, Magnenat JL, Bronson RT, Cao J, Gargano M, Sugawara M, et al. Mice deficient in cellular glutathione peroxidase develop normally and show no increased sensitivity to hyperoxia. The Journal of biological chemistry. 1997; 272(26):16644–51. PMID: 9195979

67. Nonn L, Williams RR, Erickson RP, Powis G. The absence of mitochondrial thioredoxin 2 causes massive apoptosis, exencephaly, and early embryonic lethality in homozygous mice. Molecular and cellular biology. 2003; 23(3):916–22. PubMed Central PMCID: PMC140716. doi: 10.1128/MCB.23.3.916-922.2003 PMID: 12529937

68. Zhang H, Go YM, Jones DP. Mitochondrial thioredoxin-2/peroxiredoxin-3 system functions in parallel with mitochondrial GSH system in protection against oxidative stress. Archives of biochemistry and biophysics. 2007; 465(1):119–26. doi: 10.1016/j.abb.2007.05.001 PMID: 17548047

69. Kipp AP, Muller MF, Goken EM, Deubel S, Brigelius-Flohe R. The selenoproteins GPx2, TrxR2 and TrxR3 are regulated by Wnt signalling in the intestinal epithelium. Biochimica et biophysica acta. 2012; 1820(10):1588–96. doi: 10.1016/j.bbagen.2012.05.016 PMID: 22683372

70. Yee M, Chess PR, McGrath-Morrow SA, Wang Z, Gelein R, Zhou R, et al. Neonatal oxygen adversely affects lung function in adult mice without altering surfactant composition or activity. American journal of physiology Lung cellular and molecular physiology. 2009; 297(4):L641–9. PubMed Central PMCID: PMC2770788. doi: 10.1152/ajplung.00159.2014 PMID: 21550015

71. Yee M, White RJ, Awad HA, Bates WA, McGrath-Morrow SA, O'Reilly MA. Neonatal hyperoxia causes pulmonary vascular disease and shortens life span in aging mice. The American journal of pathology. 2011; 178(6):2601–10. PubMed Central PMCID: PMC3124332. doi: 10.1016/j.ajpath.2011.02.010 PMID: 21550015

72. Jorgenson TC, Tonissen KF. Thioredoxin and Cancer: A Role for Thioredoxin in all States of Tumor Oxygenation. Cancers. 2010; 2(2):209–32. PubMed Central PMCID: PMC3835076. doi: 10.3390/cancers2020209 PMID: 24281068

73. Eriksson SE, Prast-Nielsen S, Flaberg E, Szekely L, Arner ES. High levels of thioredoxin reductase 1 modulate drug-specific cytotoxic efficacy. Free radical biology & medicine. 2009; 47(11):1661–71. doi: 10.1016/j.freeradbiomed.2009.09.016 PMID: 19943195

74. Ho YS. Transgenic and knockout models for studying the role of lung antioxidant enzymes in defense against hyperoxia. American journal of respiratory and critical care medicine. 2002; 166(12 Pt 2):SS1–6.

75. Eriksson SE, Prast-Nielsen S, Flaberg E, Szekely L, Arner ES. High levels of thioredoxin reductase 1 modulate drug-specific cytotoxic efficacy. Free radical biology & medicine. 2009; 47(11):1661–71. doi: 10.1016/j.freeradbiomed.2009.09.016 PMID: 19943195

76. Tolle LB, Standiford TJ. Danger-associated molecular patterns (DAMPs) in acute lung injury. The Journal of pathology. 2013; 229(2):145–56. doi: 10.1002/path.4124 PMID: 23097158

77. Karlenius TC, Tonissen KF. Thioredoxin and Cancer: A Role for Thioredoxin in all States of Tumor Oxygenation. Cancers. 2010; 2(2):209–32. PubMed Central PMCID: PMC3835076. doi: 10.3390/cancers2020209 PMID: 24281068

78. Jorgenson TC, Zhong W, Oberley TD. Redox imbalance and biochemical changes in cancer. Cancer research. 2013; 73(20):6118–23. PubMed Central PMCID: PMC3800221. doi: 10.1158/0008-5472.CAN-13-1117 PMID: 23878188

79. Eriksson SE, Prast-Nielsen S, Flaberg E, Szekely L, Arner ES. High levels of thioredoxin reductase 1 modulate drug-specific cytotoxic efficacy. Free radical biology & medicine. 2009; 47(11):1661–71. doi: 10.1016/j.freeradbiomed.2009.09.016 PMID: 19943195

80. Ho YS. Transgenic and knockout models for studying the role of lung antioxidant enzymes in defense against hyperoxia. American journal of respiratory and critical care medicine. 2002; 166(12 Pt 2):SS1–6.

81. Tsan MF, White JE, Caska B, Epstein CJ, Lee CY. Susceptibility of heterozygous MnSOD gene-knockout mice to oxygen toxicity. American journal of respiratory and cellular biology. 1998; 19(1):114–20. doi: 10.1165/ajrccm.19.1.3066 PMID: 9651187